Small inhibitory RNA - A tool for credentialing candidate genes

Pharmacogenomics

Volumn 6, Issue 3, 2005, Pages 281-292

  Walgren, Richard A ^a   McLeod, Howard L ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

6 thioguanine; Candidate genes; Cisplatin; Doxorubicin; Drug pathway; Hydroxyurea; Irinotecan; Pharmacogenetics; siRNA; Taxol

Indexed keywords

ANAPHASE PROMOTING COMPLEX; ATR PROTEIN; CAMPTOTHECIN; CHECKPOINT KINASE 1; CISPLATIN; CYCLOSPORIN; DOXORUBICIN; ETOPOSIDE; FLICE INHIBITORY PROTEIN; FOCAL ADHESION KINASE; GLYCOPROTEIN P; HYDROXYUREA; IRINOTECAN; PACLITAXEL; PROTEIN BCL 2; SMALL INTERFERING RNA; SYNAPTOTAGMIN; TAXANE DERIVATIVE; TIOGUANINE; TRANSCRIPTION FACTOR FOXO; VERAPAMIL; VINBLASTINE;

ARTICLE; DRUG EFFECT; DRUG MECHANISM; DRUG METABOLISM; DRUG RESISTANCE; GENE IDENTIFICATION; GENE INTERACTION; GENE SILENCING; GENETIC VARIABILITY; HUMAN; NONHUMAN; PROTEIN FUNCTION; REGULATORY MECHANISM; RNA INTERFERENCE;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENE SILENCING; GENE TARGETING; HUMANS; MODELS, BIOLOGICAL; PHARMACOGENETICS; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 18044362103     PISSN: 14622416     EISSN: None     Source Type: Journal    
DOI: 10.1517/14622416.6.3.281     Document Type: Article

References (67)

1. Evans WE, McLeod HL: Pharmacogenomic-drug disposition, drug targets, and side effects. N. Engl. J Med. 348, 538-549 (2003).
2. West DB, Iakougova O, Olsson C, Ross D, Ohmen J, Chatterjee A: Mouse genetics/genomics: an effective approach for drug target discovery and validation. Med. Res. Rev. 20, 216-230 (2000).
3. Brown SD, Balling R: Systematic approaches to mouse mutagenesis. Curr. Opin. Genet. Dev. 11, 268-273 (2001).
4. Opalinska JB, Gewirtz AM: Nucleic-acid therapeutics: basic principles and recent applications. Nat. Rev. Drug. Discov. 1, 503-514 (2002).
5. Opalinska JB, Gewirtz AM: Therapeutic potential of antisense nucleic acid molecules. Sci. STKE 2003, pe47 (2003).
6. Phillips MI, Zhang YC: Basic principles of using antisense oligonucleotides in vivo. Methods Enzymol. 313, 46-56 (2000).
7. Grunweller A, Wyszko E, Bieber B, Jahnel R, Erdmann VA, Kurreck J: Comparison of different antisense strategies in mammalian cells using locked nucleic acids, 2′-O-methyl RNA, phosphorothioates and small interfering RNA. Nucleic Acids Res. 31, 3185-3193 (2003).
8. Geary RS, Henry SP, Grillone LR: Fomivirsen: clinical pharmacology and potential drug interactions. Clin. Pharmacokinet. 41, 255-260 (2002).
9. Zamore PD, Tuschl T, Sharp PA, Bartel DP: RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell 101, 25-33 (2000).
10. Elbashir SM, Martinez J, Patkaniowska A, Lendeckel W, Tuschl T: Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate. Embo J. 20, 6877-6888 (2001).
11. Grishok A, Pasquinelli AE, Conte D et al.: Genes and mechanisms related to RNA interference regulate expression of the small temporal RNAs that control C. elegans developmental timing. Cell 106, 23-34 (2001).
12. Knight SW, Bass BL: A role for the RNase III enzyme DCR-1 in RNA interference and germ line development in Caenorhabditis elegans. Science 293, 2269-2271 (2001).
13. Hammond SM, Bernstein E, Beach D, Hannon GJ: An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells. Nature 404, 293-296 (2000).
14. Hannon GJ: RNA interference. Nature 418, 244-251 (2002).
15. Hutvagner G, Zamore PD: A microRNA in a multiple-turnover RNAi enzyme complex. Science 297, 2056-2060 (2002).
16. Hurvagner G, Simard MJ, Mello CC, Zamore PD: Sequence-specific inhibition of small RNA function. PLoS Biol. 2, E98 (2004).
17. McManus MT, Sharp PA: Gene silencing in mammals by small interfering RNAs. Nat. Rev. Genet. 3, 737-747 (2002).
18. Wianny F, Zernicka-Goetz M: Specific interference with gene function by double-stranded RNA in early mouse development. Nat. Cell. Biol. 2, 70-75 (2000).
19. Donze O, Picard D: RNA interference in mammalian cells using siRNAs synthesized with T7 RNA polymerase. Nucleic Acids Res. 30, e46 (2002).
20. Weil D, Garcon L, Harper M, Dumenil D, Dautry F, Kress M: Targeting the kinesin Eg5 to monitor siRNA transfection in mammalian cells. Biotechniques 33, 1244-1248 (2002).
21. Chen J, Wall NR, Kocher K et al.: Stable expression of small interfering RNA sensitizes TEL-PDGFβR to inhibition with imatinib or rapamycin. J. Clin. Invest. 113, 1784-1791 (2004).
22. Gupta S, Schoer RA, Egan JE, Hannon GJ, Mittal V: Inducible, reversible, and stable RNA interference in mammalian cells. Proc. Natl Acad. Sci. USA 101, 1927-1932 (2004).
23. Duxbury MS, Ito H, Benoit E, Zinner MJ, Ashley SW, Whang EE: RNA interference targeting focal adhesion kinase enhances pancreatic adenocarcinoma gemcitabine chemosensitivity. Biochem. Biophys. Res. Commun. 311, 786-792 (2003).
24. Wu H, Hait WN, Yang JM: Small interfering RNA-induced suppression of MDR1 (P-glycoprotein) restores sensitivity to multidrug-resistant cancer cells. Cancer Res. 63, 1515-1519 (2003).
25. Guo J, Verma UN, Gaynor RB, Frenkel EP, Becerra CR: Enhanced chemosensitivity to irinotecan by RNA interference-mediated down-regulation of the nuclear factor-κB p65 subunit. Clin. Cancer Res. 10,3333-3341 (2004).
26. Sudo T, Nitta M, Saya H, Ueno NT: Dependence of paclitaxel sensitivity on a functional spindle assembly checkpoint. Cancer Res. 64, 2502-2508 (2004).
27. Bergamaschi D, Gasco M, Hiller L et al.: p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell 3, 387-402 (2003).
28. Kawasaki H, Taira K: Induction of DNA methylation and gene silencing by short interfering RNAs in human cells. Nature (2004).
29. Morris KV, Chan SW, Jacobsen SE, Looney DJ: Small interfering RNA-induced transcriptional gene silencing in human cells. Science (2004).
30. Sudakin V, Chan GK, Yen TJ: Checkpoint inhibition of the APC/C in HeLa cells is mediated by a complex of BUBR1, BUB3, CDC20, and MAD2. J. Cell. Biol. 154, 925-936 (2001).
31. Yu H: Regulation of APC-Cdc20 by the spindle checkpoint. Curr. Opin. Cell Biol. 14, 706-714 (2002).
32. Sunters A, Fernandez de Mattos S, Stahl M et al.: FoxO3a transcriptional regulation of Bim controls apoptosis in paclitaxel-treated breast cancer cell lines. J. Biol. Chem. 278, 49795-49805 (2003).
33. Wang CY, Cusack JC Jr, Liu R, Baldwin AS Jr: Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB. Nat. Med. 5, 412-417 (1999).
34. Jones DR, Broad RM, Madrid LV, Baldwin AS Jr, Mayo MW: Inhibition of NF-κB sensitizes non-small cell lung cancer cells to chemotherapy-induced apoptosis. Ann. Thorac. Surg. 70, 930-936; discussion 936-937 (2000).
35. Fink D, Aebi S, Howell SB: The role of DNA mismatch repair in drug resistance. Clin. Cancer Res. 4, 1-6 (1998).
36. Li GM: The role of mismatch repair in DNA damage-induced apoptosis. Oncol. Res. 11, 393-400 (1999).
37. Yan T, Berry SE, Desai AB, Kinsella TJ: DNA mismatch repair (MMR) mediates 6-thioguanine genotoxicity by introducing single-strand breaks to signal a G2-M arrest in MMR-proficient RKO cells. Clin. Cancer Res. 9, 2327-2334 (2003).
38. Yamane K, Taylor K, Kinsella TJ: Mismatch repair-mediated G2/M arrest by 6-thioguanine involves the ATR-Chk1 pathway. Biochem. Biophys. Res. Commun. 318, 297-302 (2004).
39. Debenham PG, Kartner N, Siminovitch L, Riordan JR, Ling V: DNA-mediated transfer of multiple drug resistance and plasma membrane glycoprotein expression. Mol. Cell. Biol. 2, 881-889 (1982).
40. Ling V: Multidrug resistance and P-glycoprotein expression. Ann. NY Acad. Sci. 507, 7-8 (1987).
41. Ford JM, Hait WN: Pharmacologic circumvention of multidrug resistance. Cytotechnology 12, 171-212 (1993).
42. Hsueh EC, Essner R, Foshag LJ et al.: Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine. J. Clin. Oncol. 20, 4549-4554 (2002).
43. Pavlick AC, Adams S, Fink MA, Bailes A: Novel therapeutic agents under investigation for malignant melanoma. Expert Opin. Investig. Drugs 12, 1545-1558 (2003).
44. Hakansson A, Gustafsson B, Abdiu A, Krysander L, Hakansson L: Bcl-2 expression in metastatic malignant melanoma. Importance for the therapeutic efficacy of biochemotherapy. Cancer Immunol. Immunother. 52, 249-254 (2003).
45. Wacheck V, Losert D, Gunsberg P et al.: Small interfering RNA targeting bcl-2 sensitizes malignant melanoma. Oligonucleotides 13, 393-400 (2003).
46. Stiewe T, Zimmermann S, Frilling A, Esche H, Putzer BM: Transactivation-deficient ΔTA-p73 acts as an oncogene. Cancer Res. 62, 3598-3602 (2002).
47. Marin MC, Jost CA, Brooks LA et al.: A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat. Genet. 25, 47-54 (2000).
48. Irwin MS, Kondo K, Marin MC, Cheng LS, Hahn WC, Kaelin WG Jr: Chemosensitivity linked to p73 function. Cancer Cell 3, 403-410 (2003).
49. Abedini MR, Qiu Q, Yan X, Tsang BK: Possible role of FLICE-like inhibitory protein (FLIP) in chemoresistant ovarian cancer cells in vitro. Oncogene (2004).
50. Irmler M, Thome M, Hahne M et al.: Inhibition of death receptor signals by cellular FLIP. Nature 388, 190-195 (1997).
51. Xiao CW, Yan X, Li Y, Reddy SA, Tsang BK: Resistance of human ovarian cancer cells to tumor necrosis factor alpha is a consequence of nuclear factor κB-mediated induction of Fas-associated death domain-like interleukin-1β-converting enzyme-like inhibitory protein. Endocrinology 144, 623-630 (2003).
52. Schaller MD: Biochemical signals and biological responses elicited by the focal adhesion kinase. Biochim. Biophys. Acta 1540, 1-21 (2001).
53. Gabarra-Niecko V, Schaller MD, Dunty JM: FAK regulates biological processes important for the pathogenesis of cancer. Cancer Metastasis Rev. 22, 359-374 (2003).
54. Jackson AL, Bartz SR, Schelter J et al.: Expression profiling reveals off-target gene regulation by RNAi. Nat. Biotechnol. 21, 635-637 (2003).
55. Boutla A, Delidakis C, Livadaras I, Tsagris M, Tabler M: Short 5-phosphorylated double-stranded RNAs induce RNA interference in Drosophila. Curr. Biol. 11, 1776-1780 (2001).
56. Amarzguioui M, Holen T, Babaie E, Prydz H: Tolerance for mutations and chemical modifications in a siRNA. Nucleic Acids Res. 31, 589-595 (2003).
57. Carrington JC, Ambros V: Role of microRNAs in plant and animal development. Science 301, 336-338 (2003).
58. Doench JG, Petersen CR Sharp PA: siRNAs can function as miRNAs. Genes Dev. 17, 438-442 (2003).
59. Saxena S, Jonsson ZO, Dutta A: Small RNAs with imperfect match to endogenous mRNA repress translation. Implications for off-target activity of small inhibitory RNA in mammalian cells. J. Biol. Chem. 278, 44312-44319 (2003).
60. Sledz CA, Holko M, de Veer MJ, Silverman RH, Williams BR: Activation of the interferon system by short-interfering RNAs. Nat. Cell. Biol. 5, 834-839 (2003).
61. Bridge AJ, Pebernard S, Ducraux A, Nicoulaz AL, Iggo R: Induction of an interferon response by RNAi vectors in mammalian cells. Nat. Genet. 34, 263-264 (2003).
62. Pebernard S, Iggo RD: Determinants of interferon-stimulated gene induction by RNAi vectors. Differentiation 72, 103-111 (2004).
63. Semizarov D, Frost L, Sarthy A, Kroeger P, Halbert DN, Fesik SW: Specificity of short interfering RNA determined through gene expression signatures. Proc. Natl Acad. Sci. USA 100, 6347-6352 (2003).
64. Kittler R, Putz G, Pelletier L et al.: An endoribonuclease-prepared siRNA screen in human cells identifies genes essential for cell division. Nature 432, 1036-1040 (2004).
65. Zheng L, Liu J, Batalov S et al.: An approach to genomewide screens of expressed small interfering RNAs in mammalian cells. Proc. Natl Acad. Sci. USA 101, 135-140 (2004).
66. Machuy N, Thiede B, Rajalingam K et al.: A global approach combining proteome analysis and phenotypic screening with RNA interference yields novel apoptosis regulators. Mol. Cell Proteomics 4, 44-55 (2005).
67. Deveraux QL, Aza-Blanc P, Wagner KW, Bauerschlag D, Cooke MP, Hampton GM: Exposing oncogenic dependencies for cancer drug target discovery and validation using RNAi. Semin. Cancer Biol. 13, 293-300 (2003).